● Engineered 3D bioprinted PEGDA scaffolds and peptide hydrogels to encapsulate adult human dermal fibroblast cells (C-013-5C), enhancing cell attachment, proliferation, and drug delivery capabilities. ● Successfully developed self-assembled peptide nanofibrous scaffolds using electrospinning, achieving a 30% improvement in stability. ● Utilized flow cytometry and fluorescence microscopy to analyze cell morphology and evaluate drug release capabilities of the scaffolds.

● Conducted comprehensive cell-based assays, including MTT assay, LIVE/ DEAD assay, DAPI staining, ALP assay, and phalloidin staining, to assess the impact of nanopeptides on cellular behavior. ● Demonstrated successful differentiation of human dermal fibroblast cells into ‘’Myofibroblasts’’ supporting tissue engineering and regenerative medicine applications.

● The utilization of advanced techniques and instruments was integral to the project, including operating a fluorescence microscope for detailed observation. ● Furthermore, I was involved in the implementation of 3D printers for fabricating intricate structures. ● My role also extended to conducting cell assays, where I proficiently executed techniques such as MTT assays, LIVE-DEAD assays, DAPI staining, ALP assays, and phalloidin staining. These activities were integral to the comprehensive investigation of the nanopeptides' impact on cellular behavior.

● My responsibilities encompassed various tasks, such as thawing frozen vials, passaging cells, freezing cells, and performing cell lysis. ● Additionally, I engaged in seeding cells in microplates and 3D structured scaffolds, particularly within the context of a nanomedicine project focused on exploring the mesenchymal stem cell properties associated with newly synthesized nano peptides.

● Assisted in a nanomedicine laboratory, specializing in cell culturing methodologies. ● Additionally, I received comprehensive training in the fundamental concepts and practical application of pharmacovigilance software, contributing to a rudimentary understanding of pharmacovigilance practices.